ImmunityBio (NASDAQ:IBRX) Sets New 1-Year High – Time to Buy?

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) reached a new 52-week high on Wednesday . The stock traded as high as $8.39 and last traded at $8.4750, with a volume of 66569461 shares. The stock had previously closed at $6.02.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European Commission authorization expands ImmunityBio’s commercial footprint across four regulatory jurisdictions quickly, including key markets and additional indications for Anktiva — a major growth catalyst for sales and addressable market. What’s Behind The Jump In ImmunityBio Stock?
• Positive Sentiment: Productive regulatory discussions and a Saudi filing/“nod” for bladder cancer (BCG-related) advance market access in Saudi Arabia — investors view this as near-term revenue upside and validation in a large, well-funded market. ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority
• Positive Sentiment: Market coverage and pre-market headlines highlighted the Saudi BCG update and growing retail interest, amplifying buying momentum. Analyst support (D. Boral Capital reaffirmed buy with a $24 PT) provides a bullish price-target narrative. How high can IBRX stock go now?
• Neutral Sentiment: Commercial performance context: Seeking Alpha notes Anktiva’s strong early commercial traction (FY25 revenue cited) and upcoming pivotal trial readouts (bladder cancer, glioblastoma) — these are major potential upside catalysts but also make valuation sensitive to trial setbacks. ImmunityBio: The Story Surrounding Anktiva So Far
• Neutral Sentiment: Reported short-interest data is anomalous/unclear (entries show zero shares / NaN); with very high trading volume, short-interest metrics may not reflect real positioning — monitor updated, reliable short-interest reports for true bearish pressure. Short Interest Data (company reports)
• Negative Sentiment: Pomerantz law firm announced an investigation on behalf of ImmunityBio investors — potential litigation or disclosure risk that could create headline-driven volatility and act as a near-term overhang. Pomerantz Law Firm Investigates Claims

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Piper Sandler boosted their target price on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. HC Wainwright raised their price objective on ImmunityBio from $8.00 to $10.00 and gave the company a “buy” rating in a report on Monday, January 26th. D. Boral Capital reiterated a “buy” rating and issued a $24.00 target price on shares of ImmunityBio in a report on Tuesday. Jefferies Financial Group raised their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, ImmunityBio presently has a consensus rating of “Moderate Buy” and an average target price of $11.80.

ImmunityBio Stock Performance

The company has a market cap of $8.41 billion, a PE ratio of -20.83 and a beta of 0.16. The firm has a fifty day simple moving average of $4.10 and a 200 day simple moving average of $2.99.

Insider Transactions at ImmunityBio

In other ImmunityBio news, Director Barry J. Simon sold 151,967 shares of ImmunityBio stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total value of $1,094,162.40. Following the completion of the sale, the director directly owned 3,091,604 shares in the company, valued at $22,259,548.80. The trade was a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christobel Selecky sold 50,000 shares of ImmunityBio stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 226,967 shares of company stock worth $1,531,912 in the last quarter. 69.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ImmunityBio

Institutional investors and hedge funds have recently made changes to their positions in the company. Mariner LLC lifted its holdings in shares of ImmunityBio by 10.5% during the fourth quarter. Mariner LLC now owns 17,814 shares of the company’s stock worth $35,000 after buying an additional 1,689 shares in the last quarter. Sanctuary Advisors LLC increased its position in ImmunityBio by 6.9% during the 4th quarter. Sanctuary Advisors LLC now owns 29,547 shares of the company’s stock worth $59,000 after purchasing an additional 1,918 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in ImmunityBio by 8.6% during the 4th quarter. Sequoia Financial Advisors LLC now owns 28,783 shares of the company’s stock worth $57,000 after acquiring an additional 2,271 shares during the last quarter. Mutual Advisors LLC boosted its position in ImmunityBio by 9.0% during the 4th quarter. Mutual Advisors LLC now owns 30,200 shares of the company’s stock worth $60,000 after buying an additional 2,500 shares during the period. Finally, Commonwealth Equity Services LLC increased its holdings in ImmunityBio by 4.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 75,776 shares of the company’s stock valued at $150,000 after purchasing an additional 3,280 shares during the period. Institutional investors own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.